The von willebrand disease treatment market size is predicted to reach US$ 905 million by 2030 from US$ 471.1 million in 2020, expanding growth at a CAGR of 6.1% from 2021 to 2030. The global von Willebrand disease treatment market has expanded significantly in the last decade due to rise in the number of patient assistance programs and promising drug pipeline & approvals.
Von Willebrand disease is an inherited bleeding disorder caused due to deficiency or dysfunction of von Willebrand factor (VWF). Moreover, genetic mutation is one of the causes of von Willebrand disease. Defects or deficiency of VWF can cause bleeding by impairing platelet adhesion or by reducing the concentration of FVIII. Various treatment options are available for the treatment of von Willebrand disease, including desmopressin, clot-stabilizing medications, replacement therapies, and contraceptives. The expansion of the global von Willebrand disease treatment market can be ascribed to an increase in number of patient assistance programs and the demand for recombinant therapies.
The von Willebrand disease treatment market growth is largely driven by factors, including increasing collaborations and partnerships between top-tier research institutes and regulatory bodies, entry of new von Willebrand disease therapies, and growing awareness related to von Willebrand disease due to a surge in the number of government initiatives and awareness programs. While research and development activities are set to play an imperative role in the expansion of the von Willebrand disease treatment market, other factors that are likely to influence the market growth include rise in demand for recombinant therapies and strong product pipeline.
Market Growth to Remain Steady amid COVID-19 Pandemic
The ongoing COVID-19 pandemic is expected to have a short-term impact on the overall growth of the global von Willebrand disease treatment market. Although the sales of medication and adoption of various therapies could see a slight dip due to the COVID-19 situation, research and development activities are expected to continue in full swing across the von Willebrand disease treatment market. Several research institutes around the world are increasingly assessing the relationship between von Willebrand disease and COVID-19 due to which, new areas pertaining to von Willebrand disease treatment are being explored. While drug development and research activities are likely to remain unaffected, the number of clinical tests and procedures could potentially witness a slight dip in 2020.
Advent of New Therapies for von Willebrand Disease Likely to Boost Market Growth
Research and development activities are set to play an important role in augmenting the growth of the global von Willebrand disease treatment market during the assessment period. The entry of new therapies and von Willebrand disease treatment, as a result of research programs and initiatives, is expected to provide a considerable boost to the global von Willebrand disease treatment market. Majorly, the management of von Willebrand disease is mainly based on the dual correction of primary hemostasis defect caused due to inherited deficiency of von Willebrand factor (VWF) and the secondary defect factor VIII coagulant activity. At present, new therapies are aimed toward addressing primary deficiency in the von Willebrand disease. Considerable research is being carried out to evaluate the efficacy of new products in different clinical situations. In addition, scientists and researchers are also focusing on testing the efficacy of new therapies and products in unexplored situations, including long-term use of prophylaxis, use in children, and during recurrent gastrointestinal bleeding.
Based on disease type, the type 1 von Willebrand disease segment dominated the global von Willebrand disease treatment market in 2020. This trend is projected to continue during the forecast period. The rise in the number of VWD cases, technological advancements, and new product launches contributed to the significant share held by the segment in 2020. Moreover, increase in patient pool for type 1 disease-Type 1 VWD accounts for 60% to 80% of the patients with VWD-is likely to drive the segment.
The type 2 von Willebrand disease segment was followed by the type 1 von Willebrand disease segment, in terms of market share, in 2020. Increasing patient pool for different type 2 VWD, i.e. type 2A, type 2B, type 2M, and type 2N, is likely to drive the segment.
In terms of drug, the desmopressin segment accounted for a prominent share of the global von Willebrand disease treatment market in 2020, owing to high effectiveness in the treatment of the disease. Desmopressin is first line of treatment for von Willebrand disease. Increasing use of desmopressin in the treatment of VWD is likely to drive the segment.
In terms of route of administration, the injection segment dominated the global von Willebrand disease treatment market, in terms of revenue, in 2020. The trend is expected to continue during the forecast period. Factors such as easy, convenient route of administration of drugs, and availability of most treatment products in injection form are likely to drive the injection segment.
In terms of gender, the women segment dominated the global von Willebrand disease treatment market, in terms of revenue, in 2020. Increasing incidence of bleeding disorders such as VWD and menorrhagia in women is likely to fuel the segment.
In terms of distribution channel, the hospital pharmacies segment led the global von Willebrand disease treatment market in terms of revenue in 2020. The trend is expected to continue during the forecast period. Rapid increase in the number of hospitals and a wide range of services available in multispecialty hospitals are likely to boost the segment during the forecast period. The retail pharmacies segment is witnessing expansion, as medicines for von Willebrand disorders are advised for longer period, which prompts patients to prefer retail stores instead of a visit to the hospitals.
In terms of region, the North America dominated the global von Willebrand disease treatment market in 2020. It was followed by Europe. Significant share held by North America can be ascribed to the presence of players with significant research and development activities in order to develop new products for the treatment VWD. Moreover, a rise in prevalence of VWD is anticipated to fuel the von Willebrand diseases treatment market in the region. According to the National Hemophilia Foundation, around 1% of the U.S. population suffers from VWD.
The von Willebrand disease treatment market in Asia Pacific is anticipated to expand at a rapid pace from 2021 to 2030. The increase in opportunities to launch new products and a surge in the demand for new treatment options are key factors that are expected to boost the von Willebrand disease treatment market in Asia Pacific.
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.
The analysts have provided a comprehensive analysis of the competitive landscape of the global von willebrand disease treatment market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.
Key players operating in the global market include Octapharma AG, Grifols, S.A., Shire plc, Bayer AG, CSL Behring, Pfizer, Inc., Akorn, Inc., and Ferring B.V.
By Disease Type
By Route of Administration
By Distribution Channel
This report focuses on von willebrand disease treatment market includes crucial information on market share, market size, and growth rate for the forecast period 2021 to 2030 at the global level, regional level and company level. From a global perspective, this report represents overall von willebrand disease treatment market size by analyzing historical data and future prospect. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics. The study includes drivers and restraints of the global von willebrand disease treatment market.
The research not only conducts forecasts in terms of value, but also evaluates the market on the basis of essential parameters, such as Year-on-Year (Y-o-Y) growth. This helps providers to recognize the future opportunities as well predictability of the market.
In order to understand and assess opportunities in this market, the report is categorically divided into five key sections on the basis of segments. The report analyzes the global market in terms of value (US$ dollers) and volume (Million Units).
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2017 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global von willebrand disease treatment market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the von willebrand disease treatment market.
The report includes country-wise and region-wise market size for the period 2017-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2017-2030.
In this study, the years considered to estimate the market size of von willebrand disease treatment are as follows:
The research methodology adopted by analysts for compiling the global von willebrand disease treatment market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global von willebrand disease treatment market.
The study objectives of this report are:
Pulmonary Arterial Hypertension Market (By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators; By Type: Branded, Generics; By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Mechanical Ventilator Market (By Product: Critical Care, Neonatal, Transport & Portable; By Ventilation Mode: Invasive, Non-invasive; By End-use: Hospitals, Home Healthcare) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Surgical display Market (By Type: Low-end, Mid-end, High-end) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Agrochemicals Market (By Product: Fertilizer, Crop Protection Chemicals, Plant Growth Regulators; By Application: Cereal & Grains, Oilseeds & Pulses, Fruits & Vegetables) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Home Infusion Therapy Market (By Product: Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors; By Application: Anti-infective, Endocrinology, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition, Specialty Pharmaceuticals) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...